Overall rank by patents
#12,814
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Aquestive Therapeutics, Inc.
USPTO PatentsView assignee record - 23 granted patents across 18 technology areas, active 2018–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
23
Total patents granted
18
CPC technology areas
22.4
Avg claims per patent
+375%
5-year filing velocity
The verdict
Aquestive holds 23 US patents across 18 technology areas, rank #12,814 of 50,000 tracked assignees.
- #12,814
- of 50,000 US assignees by volume
- Top 31%
- by Innovation Score (42.2/100)
- 22.4
- avg claims per patent
- +375%
- filing velocity, last 5 yrs
Portfolio overview
Aquestive Therapeutics, Inc. has been granted 23 US utility patents between 2018 and 2025, placing Aquestive Therapeutics, Inc. at rank #12,814 across all assignees tracked by PlainPatent. This portfolio spans 18 distinct Cooperative Patent Classification (CPC) subclasses, averaging 22.4 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Aquestive Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 42.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 19 grants, compared with 4 in the 2015–2019 window, a +375% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Aquestive Therapeutics, Inc.'s 22.4 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 18 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Aquestive Therapeutics, Inc. against peers pursuing similar technology classes.
How does Aquestive compare?
Granted US patents 2015–2025 versus the largest corporate holders, this company marked ◀
- Samsung
SAMSUNG ELECTRONICS CO., LTD.
106,890 patents
- International Bus…
International Business Machines Corporation
72,926 patents
- Canon 34,378
Canon Kabushiki Kaisha
34,378 patents
- LG 32,607
LG ELECTRONICS INC.
32,607 patents
- Taiwan Semiconduc… 31,041
TAIWAN SEMICONDUCTOR MANUFACTURING COMPANY LTD.
31,041 patents
- Apple 30,560
Apple Inc.
30,560 patents
- Qualcomm Incorpor… 30,354
QUALCOMM Incorporated
30,354 patents
- Intel 27,498
Intel Corporation
27,498 patents
- Aquestive Therape… ◀ 23
Aquestive Therapeutics, Inc.
23 patents
What this shows Aquestive holds 23 patents, placing it at rank #12,814 overall, well behind the volume leaders but ahead of the tens of thousands of smaller assignees in the dataset.
Aquestive's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
42 Top 31% higher than 69% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
USPTO utility patent grants by year · 2018–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2018 | 2 | 8.7% |
| 2019 | 2 | 8.7% |
| 2020 | 2 | 8.7% |
| 2021 | 8 | 34.8% |
| 2022 | 1 | 4.3% |
| 2023 | 2 | 8.7% |
| 2024 | 2 | 8.7% |
| 2025 | 4 | 17.4% |
Which technologies does Aquestive Therapeutics, Inc. patent most?
Top 15 of 18 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Accelerating
Frequently Asked Questions
How many patents does Aquestive Therapeutics, Inc. hold?
Aquestive Therapeutics, Inc. holds 23 US granted patents filed between 2018 and 2025, spanning 18 technology areas.
What is Aquestive Therapeutics, Inc.'s Innovation Score?
Aquestive Therapeutics, Inc. has an Innovation Score of 42.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Aquestive Therapeutics, Inc. focus on?
Aquestive Therapeutics, Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 17 patents. The company has filed patents in 18 CPC subclasses total.
Is Aquestive Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Aquestive Therapeutics, Inc.'s recent filing velocity is +375% compared to the prior five-year period. This indicates accelerating innovation.
What does claim depth mean for Aquestive Therapeutics, Inc.'s patents?
Aquestive Therapeutics, Inc.'s patents average 22.4 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Aquestive Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
Guides to patent portfolio analysis
How to use this portfolio
Aquestive's 23 grants land it in the top 31% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Aquestive ranks #12,814 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Explore the patent dataset
A61K technology
Aquestive Therapeutics, Inc.'s primary CPC class, all holders and yearly trends
Top 50 patent holders
See where Aquestive Therapeutics, Inc. ranks among the largest US patent assignees
All technology classes
Browse every CPC technology area by patent activity
How the score works
The four dimensions behind the Innovation Score
Related
Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent Editorial
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Data sources used on this page
- USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
- Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
- USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov
